Historical Financials in USD and H12025 OPEX (Unaudited)
Filed with ASX · · 10 pages · English
Summary by 6ix AI
Telix Pharmaceuticals Limited has released an unaudited recast of its historical financial information in USD, following a change in reporting currency from Australian dollars, to assist investors with upcoming financial reports. The recast includes full-year and half-year information for the previous two financial years to facilitate comparisons with future results. Additionally, the filing outlines expected operating expenditure for the first half of the upcoming year, reflecting the company's expanded business activities. This announcement serves to provide clarity on financial performance as Telix transitions to USD reporting.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix H1 2025 Results: Investor Webcast Notification
- Telix Reports US$204M Q2 Revenue, Up 63% YOY
- Gozellix Receives Permanent HCPCS Code
- Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
- Telix Precision Medicine Announces AlFluor Radiochemistry Platform
Later from Telix Pharmaceuticals
- Telix H1 2025 Appendix 4D and Interim Report
- Telix H1 2025 Results Presentation
- Telix H1 2025 Results Announcement
- Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
- Telix Provides Regulatory Update on TLX250-CDx
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals